

# Epidemiology of Sepsis-associated Acute Kidney Injury in Beijing, China : a descriptive analysis

**Haiman Wang**

Beijing Friendship Hospital

**Xiaojun Ji**

Beijing Friendship Hospital

**Amanda Y Wang**

UNSW Sydney

**Patrick Wu**

Queen Mary Hospital

**Zhuang Liu**

Beijing Friendship Hospital

**Lei Dong**

Beijing Friendship Hospital

**Jingfeng Liu**

Beijing Friendship Hospital

**Pei Liu**

Beijing Friendship Hospital

**Zhili Qi**

Beijing Friendship Hospital

**Meili Duan** (✉ [dmeili@bfh.com.cn](mailto:dmeili@bfh.com.cn))

Beijing Friendship Hospital

---

## Research Article

**Keywords:** Epidemiology, Sepsis-associated acute kidney injury, Traditional Chinese medicine hospitals, Western medicine hospitals

**Posted Date:** March 2nd, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-136890/v2>

**License:** © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background** Sepsis is the most common contributing factor towards development of acute kidney injury (AKI), which is strongly associated to poor prognostic outcomes. There are numerous epidemiological studies about sepsis-associated acute kidney injury (S-AKI), however current literature is limited with the majority of studies being conducted only in the intensive care unit (ICU) setting. The aim of this study was to assess the epidemiology of S-AKI in all hospitalized in-patients.

**Methods** This was a retrospective population-based study using a large regional population database in Beijing city from January, 2005 to December, 2017. It included patients with S-AKI. Patients with pre-existing end-stage kidney disease (ESKD), previous history of kidney transplantation, or being pregnant were excluded. Patients' demographic characteristics, incidence, risk factors and outcomes of S-AKI were analyzed. The differences between different time periods, different levels of hospitals, and types of the hospitals (i.e. traditional Chinese medicine hospitals (TCMHs) and Western medicine hospitals (WMHs)) were also compared using Mann-Whitney U test.

**Results** A total of 19,579 patients were included. The overall incidence of S-AKI in all in-patients was 48.1%. The risk factors for AKI included: age ( $P < 0.001$ ), male ( $P < 0.001$ ), treatment in a level-II hospital ( $P < 0.001$ ) and so on. The overall mortality rate in this cohort was 55%. The risk factors for mortality included: age ( $P < 0.001$ ), female ( $P < 0.001$ ), pre-existing chronic kidney disease (CKD) ( $P = 0.023$ ) and so on. The incidence of S-AKI increased over time, but the mortality rate did not. Compared with level-II hospitals, the incidence of S-AKI was similar in tertiary hospitals, but the mortality rate was significantly higher.

Although patients treated in TCMHs had a shorter hospital stay and a lower cost of care, this cohort had a higher mortality rate when compared with patients treated in WMHs.

**Conclusions** AKI is a common complication in all hospitalized patients with sepsis, and its incidence increases over time, especially when ICU admission is required. Exploring interventional strategies to address modifiable risk factors will be important to reduce incidence and mortality of S-AKI.

## Background

Acute Kidney Injury (AKI) is common in critically ill patients. Approximately one out of three patients in intensive care unit (ICU) develop AKI, and its incidence is increasing from 35.8–50.4%<sup>1–5</sup>.

Critically ill patients with AKI carries high mortality rates of up to 60%<sup>6</sup>. Survivors following an episode of severe AKI in ICU have an increased risk of developing chronic kidney disease and end-stage kidney disease, cardiovascular disease and are associated with reduced quality of life<sup>7,8</sup>.

Sepsis remains the most common cause of AKI in the critically ill patients<sup>7,9</sup>. There are numerous studies that have evaluated the epidemiology of S-AKI. The largest study to date by Bagshaw et al<sup>10</sup>, involving

57 Australian ICUs with > 120,000 critically ill patients, reported a S-AKI incidence of only 11.7%. However, the incidence of S-AKI was reported higher in the Chinese literature, ranging from 45%-51%<sup>5,11,12</sup>. The difference in incidence could be attributed to differences in ethnic backgrounds and different AKI diagnostic criteria used in different studies. Furthermore, the existing studies on incidence of S-AKI in Chinese population were mainly derived from ICU data, which is not representative of the whole population. Furthermore, there is paucity of information on incidence and outcomes of S-AKI among different levels and types of healthcare system.

Therefore, the objective of this study was to assess the epidemiology of S-AKI in both ICU and non-ICU patients from all the level-II and tertiary hospitals in Beijing, China. The study also compares the differences between the level-II and tertiary level of hospitals as well as between TCMHs and WMHs on the incidence and outcomes of S-AKI, in order to provide greater insight into the burden of this condition in China, which is essential for the planning and assessment of interventional strategies to improve clinical outcomes.

## Methods

### Study population

We conducted this retrospective study including hospitalized patients from 1 January, 2005 to 31 December, 2017 in Beijing, China. Patients with S-AKI were identified using the Primary International Classification of Diseases, 10th revision (ICD-10) codes.

The inclusion criteria consisted of: (1) adult patients (age  $\geq$  18 years), (2) hospital stay longer than 24 hour in duration and (3) diagnosis consistent with sepsis (A41.9 based on ICD-10 classification).

The exclusion criteria consisted of: (1) pre-existing end-stage kidneydisease (ESKD), (2) patients who had received kidney transplantation or (3) pregnant patients. All methods in this study were performed in accordance with the relevant guidelines and regulations. This study was approved by the research ethics committee of Beijing Friendship Hospital (Reference Number: 2020-P2-089-01). Because this was a retrospective observational study, an informed consent was exempted by the research ethics committee of Beijing Friendship Hospital.

### Definitions of S-AKI

Since the publication of the RIFLE consensus classification for AKI, and the modifications by the Acute Kidney Injury Network (AKIN), and Kidney Disease Improving Global Outcomes (KDIGO), these definitions have been used in the majority of studies reporting on AKI<sup>13-15</sup>.

Our AKI definition followed the AKIN criteria<sup>15</sup> from the 2005–2011 period and the KIDGO criteria from 2012 onwards<sup>13</sup>. Given that the values of serum creatinine level and urine volume could not be obtained, the diagnosis of AKI was extrapolated directly from the database using the ICD-10 code. We used the A41.9 code as the diagnosis of sepsis and the N17.9 code as the diagnosis of AKI.

## Statistical analysis

Patients' demographic characteristics were presented using proportions for categorical variables, mean (standard deviation) or median (interquartile range) as appropriate for continuous variables. Continuous variables were compared using the Student's t-test or Mann-Whitney U test according to data distribution, while categorical variables were compared using the chi-square test. Based on existing knowledge, the following variables: age, age stratification<sup>16</sup>, gender, hospital levels, time interval, comorbidities (including diabetes mellitus (DM), hypertension (HT), CKD stage 2 and stage 3, malignancy and cirrhosis)<sup>17–20</sup>, ICU admission, types of infection and types of organ function damage<sup>4</sup> were selected and constructed in multivariate analysis to assess the risk factors of S-AKI.

Logistic regression was used to assess the associations of patients characteristics including age, gender, medical insurance patterns, hospital levels, comorbidities, infection sites, presence of organ dysfunction with AKI among patients with sepsis, and with in-hospital death in patients with AKI, respectively.

Pre-specified subgroup analyses included level II versus tertiary hospitals, TCMHs versus WMHs, and pre-KDIGO guideline era (2005–2011) and post-KDIGO guideline era (2012–2017).

Participants were divided into four subgroups based on age: 18–39 years old, 40–59 years old, 60–79 years old, 80 years old and above.

Log-rank tests were used to compare hospital survival rates between groups. A p value of < 0.05 was considered statistically significant. All analyses were conducted with SAS 9.4 (SAS Institute Inc., Cary, North Carolina).

## Results

Among 108,848 patients' data obtained from a hospitalised registration system in Beijing, China, a total of 40,720 septic patients were included in the final analysis, of which 19,579 met the criteria for S-AKI. The average age was 78 years old, with 62.7% were male. Majority of the patients (90.1%) were admitted to a tertiary hospital who were generally admitted from the emergency department (60%).

Compared with septic patients without concurrent AKI, S-AKI patients were older, predominantly male, and have more significant comorbidities (including HT, DM, chronic kidney disease (CKD), cirrhosis and underlying malignancy).

Patients who experienced an episode of shock of any form (i.e. hypovolaemic, cardiogenic or septic) were more susceptible to AKI. Majority of the patients (77.4%) with S-AKI had pneumonia. Approximately, every 1 in 3 patients (34.3%) with S-AKI required an ICU admission. Compared with septic patients without concurrent AKI, patients with S-AKI had longer hospital length of stays and were associated with significantly higher average daily costs ( $P < 0.001$ ) and overall costs ( $P < 0.001$ ). The demographic and clinical characteristics of these patients are presented in Table 1.

Table 1  
Baseline clinical characteristics of sepsis patients with and without AKI

Variables		Sepsis with AKI (n = 19579)	Sepsis without AKI(n = 21141)	P value
Age median [IQR]		78(64–84)	75(59–83)	< 0.001
Age stratification(years)	18–39	949(4.8)	1703(8)	< 0.001
	40–59	2663(13.6)	3633(17.2)	
	60–79	7304(37.2)	7761(36.7)	
	≥ 80	8693(44.3)	8059(38.1)	
Gender	Female	7294(37.3)	8272(39.1)	< 0.001
	Male	12285(62.7)	12869(60.9)	
Classification of insurance	BMI	10825(55.3)	11601(54.9)	< 0.001
	RCMTI	1485(7.6)	1612(7.6)	
	GMP	3306(16.9)	3345(15.8)	
	OPP	1261(6.4)	1175(5.6)	
	Others	2702(13.8)	3408(16.1)	
Hospital level	Tertiary hospitals	17519(89.5)	19151(90.6)	< 0.001
	Second-class hospital	2060(10.5)	1990(9.4)	
Hospital nature	Western Medicine hospital	18006(92)	19412(91.8)	0.59
	Hospital of TCM	1573(8)	1729(8.2)	
Time interval(year)	2005–2011	1468(7.5)	2228(10.5)	< 0.001
	2012–2017	18111(92.4)	18913(89.4)	
Comorbidities(n)	Diabetes	7024(35.8)	6571(31.1)	< 0.001

Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCM = traditional Chinese medicine. Values are expressed as the median (interquartile range and N (%)).

Variables		Sepsis with AKI (n = 19579)	Sepsis without AKI(n = 21141)	P value
	Hypertension	10227(52.2)	9573(45.2)	< 0.001
	CKD stage 2 and 3	2944(15)	1655(7.8)	< 0.001
	Malignancy	3750(19.1)	3832(18.1)	0.01
	Cirrhosis	800(4.1)	592(2.8)	< 0.001
ICU		6725(34.3)	4642(21.9)	< 0.001
Types of shock	No shock	14617(74.5)	19233(90.9)	< 0.001
	Septic shock	3422(17.5)	1073(5.1)	< 0.001
	Hypovolemic shock	988(5)	593(2.8)	< 0.001
	Cardiac shock	939(4.8)	357(1.7)	< 0.001
	Two or more kinds of shock	345(1.8)	96(0.5)	< 0.001
Types of infection	Pneumonia	15176(77.4)	14858(70.2)	< 0.001
	Urinary infection	1492(7.6)	1906(9)	< 0.001
	Intra-abdominal infection	1782(9.1)	1792(8.5)	0.03
	CRBSI	657(3.4)	472(2.2)	< 0.001
	CNS infection	47(0.2)	67(0.3)	0.14
	Others	3229(16.5)	4510(21.3)	< 0.001
Types of organ function damage	Respiratory insufficiency	11797(60.2)	8032(38)	< 0.001

Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCM = traditional Chinese medicine. Values are expressed as the median (interquartile range and N (%)).

Variables		Sepsis with AKI (n = 19579)	Sepsis without AKI(n = 21141)	P value
	Acute liver injury	4000(20.4)	3518(16.6)	< 0.001
	DIC	680(3.5)	195(0.9)	< 0.001
	MODS	3386(17.3)	1117(5.3)	< 0.001
	Metabolic encephalopathy	238(1.2)	124(0.6)	< 0.001
Expenses	Total expense (Yuan)	60242.42(28580.86-122460.29)	39853.56(18844.39-81420.71)	< 0.001
	Average daily expense (Yuan)	5272.18(3190.64-8583.87)	3224.33(1862.96-5593.4)	< 0.001
	Western medicine expense (Yuan)	13885.26(5645.02-30424.3)	9700.77(3298.62-22050.47)	< 0.001
	Chinese medicine expense (Yuan)	94.74(0-854.43)	77.75(0-623.56)	< 0.001
Outcome	Length of hospital stay (day)	13(6–23)	13(7–22)	< 0.001
	Death(n)	10647(55)	6157(29.3)	< 0.001
Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCM = traditional Chinese medicine. Values are expressed as the median (interquartile range and N (%)).				

### Incidence and risk factors of S-AKI

The incidence of S-AKI in all inpatients was 48.1%, which was higher in ICU patients than non-ICU patients (59.2% versus 31.6%,  $p < 0.001$ ).

In multivariate analysis, the following independent risk factors for S-AKI were identified: age (odds ratio(OR) = 1.00, 95%CI (1.00–1.00),  $P < 0.001$ ), male (OR = 1.13, 95%CI (1.08–1.19),  $P < 0.001$ ), uninsured (OR = 1.33, 95%CI (1.47–1.22),  $P < 0.001$ ), being treated in a level-II hospital (OR = 1.18, 95%CI (1.10–1.27),  $P < 0.001$ ), pre-existing hypertension (OR = 1.20, 95%CI (1.14–1.26),  $P < 0.001$ ), CKD (OR = 1.94, 95%CI (1.80–2.08),  $P < 0.001$ ), malignancy (OR = 1.20, 95%CI (1.14–1.26),  $P < 0.001$ ), cirrhosis (OR = 1.69, 95%CI (1.49–1.91),  $P < 0.001$ ), emergency admission (OR = 1.69, 95%CI (1.49–1.91),  $P < 0.001$ ), ICU admission (OR = 1.2, 95%CI (1.14–1.26),  $P < 0.001$ ), shock (OR = 1.2, 95%CI (1.14–1.26),  $P < 0.001$ ),

pneumonia (OR = 1.33, 95%CI (1.18–1.49),  $P < 0.001$ ), intra-abdominal infection (OR = 1.46, 95%CI (1.32–1.61),  $P < 0.001$ ), bloodstream infection (OR = 1.51, 95%CI (1.32–1.73),  $P < 0.001$ ), acute respiratory failure (OR = 1.93, 95%CI (1.84–2.03),  $P < 0.001$ ), disseminated intravascular coagulation (OR = 2.15, 95% CI (1.75–2.65),  $P < 0.001$ ).

**All-cause mortality and risk factors** (Table 2)

Table 2  
Risk factors associated with death of S-AKI

Variables		Survivor	Death	P value
N (%)		8712(45.0)	10647(55.0)*	
Age median [IQR]		76(60–84)	79(68–85)	< 0.001
Age stratification(years)	18–39	575(6.6)	358(3.4)	< 0.001
	40–59	1487(17.1)	1134(10.7)	
	60–79	3212(36.9)	3983(37.4)	
	≥ 80	3438(39.5)	5172(48.6)	
Gender	Female	3182(36.5)	4029(37.8)	0.06
	Male	5530(63.5)	6618(62.2)	
Classification of insurance	BMI	3929(45.1)	6818(64)	< 0.001
	RCMTI	958(11)	483(4.5)	
	GMP	1890(21.7)	1415(13.3)	
	OPP	622(7.1)	639(6)	
	Others	1313(15.1)	1292(12.1)	
Hospital level	Tertiary hospitals	7953(91.3)	9370(88)	< 0.001
	Second-class hospital	759(8.7)	1277(12)	
Hospital nature	Western Medicine hospital	8200(94.1)	9603(90.2)	0.59
	Hospital of TCM	512(5.9)	1044(9.8)	
Time interval(year)	2005–2011	450(5.2)	798(7.5)	< 0.001
	2012–2017	8262(94.8)	9849(92.5)	

Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCM = traditional Chinese medicine. Values are expressed as the median (interquartile range and N (%)). \* 220 missing values because of lacking of outcome indicators.

Variables		Survivor	Death	P value
Comorbidities(n)	Diabetes	3475(39.9)	3513(33)	< 0.001
	Hypertension	4785(54.9)	5394(50.7)	< 0.001
	CKD stage 2 and 3	1134(13)	1804(16.9)	< 0.001
	Malignancy	1288(14.8)	2430(22.8)	< 0.001
	Cirrhosis	305(3.5)	495(4.6)	< 0.001
ICU		3136(36)	3589(33.7)	< 0.001
Types of shock	No shock	7179(82.4)	7400(69.5)	< 0.001
	Septic shock	1032(11.8)	2178(20.5)	< 0.001
	Hypovolemic shock	380(4.4)	607(5.7)	< 0.001
	Cardiac shock	190(2.2)	745(7)	< 0.001
	Two or more kinds of shock	67(0.8)	273(2.6)	< 0.001
Types of infection	Pneumonia	6508(74.7)	8527(80.1)	< 0.001
	Urinary infection	898(10.3)	576(5.4)	< 0.001
	Intra-abdominal infection	794(9.1)	967(9.1)	0.94
	CRBSI	275(3.2)	377(3.5)	0.14
	CNS infection	20(0.2)	27(0.3)	0.74
	Others	1568(18)	1580(14.8)	< 0.001

Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCM = traditional Chinese medicine. Values are expressed as the median (interquartile range and N (%)). \* 220 missing values because of lacking of outcome indicators.

Variables		Survivor	Death	P value
Types of organ function damage	Respiratory insufficiency	4571(52.5)	7135(67)	< 0.001
	Acute liver injury	1780(20.4)	2199(20.7)	0.7
	DIC	205(2.4)	473(4.4)	< 0.001
	MODS	1132(13)	2238(21)	< 0.001
	Metabolic encephalopathy	112(1.3)	126(1.2)	0.52
Expenses	Total expense (Yuan)	58362.5(29533.66-114864.4)	62520.49(27564.02-130377.97)	0.02
	Average daily expense (Yuan)	4673.41(2681.64-7898.79)	5823.35(3670.61-9187.57)	< 0.001
	Western medicine expense (Yuan)	13422.67(5867.98-28107.39)	14098.64(5414.67-32046.23)	0.01
	Chinese medicine expense (Yuan)	142.69(0-1087.74)	68.98(0-693.93)	< 0.001
Outcome	Length of hospital stay (day)	14(7–24)	12(4–22)	< 0.001
Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCM = traditional Chinese medicine. Values are expressed as the median (interquartile range and N (%)). * 220 missing values because of lacking of outcome indicators.				

There were 220 missing values because of lack of in-hospital outcomes. Overall all-cause mortality in S-AKI patients were 55%. Majority of them (57.9% of non-survivors) were admitted to ICU. The mortality in ICU patients was lower at 53.4%, compared to 54.8% in non-ICU patients ( $P < 0.001$ ).

Patients with pneumonia had significantly higher mortality rates than those without ( $P < 0.001$ ). Patients with more severe multi-functional organ dysfunction syndrome was also associated with increased mortality, and had significantly higher overall costs ( $p = 0.02$ ) and average daily costs ( $P < 0.001$ ).

A multivariate regression analysis revealed that risk factors for mortality included age (OR = 1.02, 95%CI (1.02–1.03),  $P < 0.001$ ), female (OR = 1.15, 95%CI (1.08–1.24),  $P < 0.001$ ), pre-existing comorbidities (CKD (OR = 1.12, 95%CI (1.02–1.24),  $P = 0.023$ ), malignancy (OR = 2.03, 95%CI (1.86–2.23),  $P < 0.001$ ), and cirrhosis (OR = 1.75, 95%CI (1.45–2.11),  $P < 0.001$ )), ICU admission (OR = 1.15, 95%CI (1.05–1.27),  $P =$

0.005),pulmonary infection (OR = 1.47, 95%CI (1.23–1.76), $P < 0.001$ ) respiratory failure (OR = 2.02, 95%CI (1.87–2.17),  $P < 0.001$ ), DIC (OR = 1.8, 95%CI (1.41–2.29),  $P < 0.001$ ) and MODS (OR = 2.07, 95%CI (1.86–2.29),  $P < 0.001$ ).We tested collinearity for relevant variables model and there was no collinearity among the included variables.

The development of AKI strongly influenced hospital survival rates in patients with sepsis (45.0% versus 70.7% in patients with and without AKI, respectively;  $p < 0.001$ ;Figure 1)

**S-AKI before and after the KDIGO guideline era (Table 3)**

Table 3

Comparison of the epidemiology of S-AKI between pre and post KDIGO guideline for AKI definition

Variables		2005–2011	2012–2017	P value
N (%)		1468(100)	18111(100)	
Death		798(63.9)	9849(54.4)	< 0.001
Age median [IQR]		75(60.5–82)	78(65–85)	< 0.001
Age stratification(years)	18–39	111(7.6)	838(4.6)	< 0.001
	40–59	238(16.2)	2419(13.4)	
	60–79	623(42.4)	6666(36.8)	
	≥ 80	496(33.8)	8188(45.2)	
Gender	Female	554(37.7)	6741(37.2)	0.69
	Male	914(62.3)	11370(62.8)	
Classification of insurance	BMI	750(51.1)	10082(55.7)	< 0.001
	RCMTI	222(15.1)	1260(7)	
	GMP	96(6.5)	3215(17.8)	
	OPP	41(2.8)	1222(6.7)	
	Others	359(24.5)	2332(12.9)	
Hospital level	Tertiary hospitals	1357(92.4)	16163(89.2)	< 0.001
	Second-class hospital	111(7.6)	1948(10.8)	
Hospital nature	Western Medicine hospital	1352(92.1)	16656(92)	0.86
	Hospital of TCM	116(7.9)	1455(8)	
Comorbidities(n)	Diabetes	257(17.5)	6763(37.3)	< 0.001

Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCM = traditional Chinese medicine. Values are expressed as the median (interquartile range and N (%)).

Variables		2005–2011	2012–2017	P value
	Hypertension	422(28.7)	9799(54.1)	< 0.001
	CKD stage 2 and 3	72(4.9)	2872(15.9)	< 0.001
	Malignancy	182(12.4)	3560(19.7)	< 0.001
	Cirrhosis	21(1.4)	779(4.3)	< 0.001
ICU		99(6.7)	6626(36.6)	< 0.001
Types of Shock	No shock	677(46.1)	13937(77)	< 0.001
	Septic shock	721(49.1)	2674(14.8)	< 0.001
	Hypovolemic shock	68(4.6)	920(5.1)	0.45
	Cardiac shock	41(2.8)	897(5)	< 0.001
	Two or more kinds of shock	39(2.7)	305(1.7)	0.01
Types of infection	Pneumonia	842(57.4)	14320(79.1)	< 0.001
	Urinary infection	144(9.8)	1347(7.4)	0.001
	Intra-abdominal infection	100(6.8)	1681(9.3)	0.002
	CRBSI	29(2)	628(3.5)	0.002
	CNS infection	3(0.2)	44(0.2)	0.77
	Others	495(33.7)	2720(15)	< 0.001
Types of organ function damage	Respiratory insufficiency	661(45)	11123(61.4)	< 0.001
	Acute liver injury	131(8.9)	3865(21.3)	< 0.001

Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCM = traditional Chinese medicine. Values are expressed as the median (interquartile range and N (%)).

Variables		2005–2011	2012–2017	P value
	DIC	199(13.6)	481(2.7)	< 0.001
	MODS	585(39.9)	2800(15.5)	< 0.001
	Metabolic encephalopathy	17(1.2)	221(1.2)	0.83
Expenses	Total expense (Yuan)	62115.33(24502.22-134419.29)	60158.84(28824.21-121703.84)	0.88
	Average daily expense (Yuan)	3859.29(2200.42-6547.85)	5406.94(3280.57-8719.52)	< 0.001
	Western medicine expense (Yuan)	25847.1(9208.77-58538.56)	13329.13(5430.34-28760.24)	< 0.001
	Chinese medicine expense (Yuan)	31.06(0-305.98)	107.58(0-917.56)	< 0.001
Length of hospital stay (day)		16(7–35)	12(6–23)	< 0.001
Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCM = traditional Chinese medicine. Values are expressed as the median (interquartile range and N (%)).				

The incidence of S-AKI post the KDIGO guideline era was higher than pre-KDIGO (48.9% versus 39.7%,  $P < 0.001$ ), but the mortality rate was significantly lower after the KDIGO guideline era (54.4% versus 63.9%,  $p < 0.001$ , Fig. 2). Comparing with the patients before the KDIGO guideline era (period 2005–2011), patients after the KDIGO guideline era (2012–2017) were older ( $p < 0.001$ ), but no gender difference was observed ( $p = 0.69$ ). In these two time periods, there were significant differences in the distribution of patients visiting tertiary and level-II hospitals ( $p < 0.001$ ): more patients started to attend level-II hospitals although the vast majority of patients still went to tertiary hospitals (10.75% versus 89.2%. ( $p < 0.001$ )). There were more S-AKI diagnosed in patients with underlying comorbidities (hypertension, CKD, cirrhosis and malignant tumors) in the post-KDIGO guideline era. Patients were also more likely to be admitted in ICU ( $p < 0.001$ ). Pneumonia ( $p < 0.001$ ) and abdominal infection ( $p = 0.002$ ) appeared to be more commonly complicated by S-AKI patients in the post KDIGO era. Although the average daily cost of patients in the second period was higher ( $p < 0.001$ ), the hospital stays were shorter ( $p < 0.001$ ), making no difference in the total cost related to the hospitalization ( $p = 0.88$ ).

#### AKI patients in both level-II and tertiary hospitals (Table 4)

Table 4  
Comparison between level II and tertiary hospitals

Variables		Level-II hospital	Tertiary hospitals	P value
N (%)		2059(100)	17520(100)	
Death		1277(62.7)	9370(54.1)	< 0.001
Age median [IQR]		80(70–85)	78(64–84)	< 0.001
Age stratification(years)	18–39	45(2.2)	904(5.2)	< 0.001
	40–59	213(10.3)	2444(13.9)	
	60–79	737(35.8)	6552(37.4)	
	≥ 80	1064(51.7)	7620(43.5)	
Gender	Female	817(39.7)	6478(37)	0.02
	Male	1242(60.3)	11042(63)	
Classification of insurance	BMI	1384(67.2)	9448(53.9)	< 0.001
	RCMTI	263(12.8)	1219(7)	
	GMP	193(9.4)	3118(17.8)	
	OPP	96(4.7)	1167(6.7)	
	Others	123(6)	2568(14.7)	
Hospital nature	Western Medicine hospital	1967(95.5)	16041(91.6)	< 0.001
	Hospital of TCM	92(4.5)	1479(8.4)	
Time Period	2005–2011	111(5.4)	1357(7.7)	< 0.001
	2012–2017	1948(94.6)	16163(92.3)	
Comorbidities(n)	Diabetes	719(34.9)	6301(36)	0.35
	Hypertension	1085(52.7)	9136(52.1)	0.64

Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCM = traditional Chinese medicine. Values are expressed as the median (interquartile range and N (%)).

Variables		Level-II hospital	Tertiary hospitals	P value
	CKD stage 2 and 3	403(19.6)	2541(14.5)	< 0.001
	Malignancy	258(12.5)	3484(19.9)	< 0.001
	Cirrhosis	40(1.9)	760(4.3)	< 0.001
ICU		613(29.8)	6112(34.9)	< 0.001
Types of shock	No shock	1593(77.4)	13021(74.3)	0.003
	Septic shock	312(15.2)	3083(17.6)	0.006
	Hypovolemic shock	108(5.2)	880(5)	0.66
	Cardiac shock	78(3.8)	860(4.9)	0.02
	Two or more kinds of shock	31(1.5)	313(1.8)	0.36
Types of infection	Pneumonia	1582(76.8)	13580(77.5)	0.49
	Urinary infection	122(5.9)	1369(7.8)	0.002
	Intra-abdominal infection	131(6.4)	1650(9.4)	< 0.001
	CRBSI	22(1.1)	635(3.6)	< 0.001
	CNS infection	3(0.1)	44(0.3)	0.36
	Others	382(18.6)	2833(16.2)	0.006
Types of organ function damage	Respiratory insufficiency	1064(51.7)	10720(61.2)	< 0.001
	Acute liver injury	286(13.9)	3710(21.2)	< 0.001
	DIC	37(1.8)	643(3.7)	< 0.001
	MODS	300(14.6)	3085(17.6)	< 0.001

Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCM = traditional Chinese medicine. Values are expressed as the median (interquartile range and N (%)).

Variables		Level-II hospital	Tertiary hospitals	P value
	Metabolic encephalopathy	28(1.4)	210(1.2)	0.53
Expenses	Total expense (Yuan)	41047.75(17598.47-92271.23)	62702.87(30227.13-125862.83)	< 0.001
	Average daily expense (Yuan)	3822.54(2297.78-6014.34)	5499.86(3329.52-8886.23)	< 0.001
	Western medicine expense (Yuan)	9085.04(3349.65-22224.82)	14510.38(5984.67-31314.93)	< 0.001
	Chinese medicine expense (Yuan)	78.04(0-650.52)	98.49(0-869.4)	0.19
Length of hospital stay (day)		13(4–25)	13(6–23)	0.15
Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCM = traditional Chinese medicine. Values are expressed as the median (interquartile range and N (%)).				

The majority of S-AKI patients (89.5%) were presented and admitted to tertiary hospitals, despite an overall increase in presentation to level-II hospitals over the observed time period. The proportion rose from 7.56% in the pre KDIGO guideline era to 10.75% in the post KDIGO guideline era ( $P < 0.001$ ). Patients over 80 years old were mostly in level-II hospitals ( $p < 0.001$ ) whilst tertiary hospitals had younger patients ( $p < 0.001$ ). Patients were predominantly male in both levels of the hospitals.

The ICU admission rate of S-AKI patients in level-II hospitals was significantly lower than that in tertiary hospitals (29.77% versus 34.89%,  $p < 0.001$ ). Compared with level-II hospitals, the proportion of patients with septic shock ( $p = 0.006$ ), abdominal infection ( $p < 0.001$ ), bloodstream infection ( $p < 0.001$ ), respiratory failure ( $p < 0.001$ ) and MODS ( $p < 0.001$ ) was higher in tertiary hospitals. Despite similar length of stay was seen in both hospitals ( $p = 0.15$ ), the total cost, and average daily cost for patients being treated in tertiary hospitals were all higher ( $p < 0.001$ ).

Both the incidence (50.8% versus 47.7%,  $p < 0.001$ ) and the mortality rate (62.1% versus 54.1%,  $p < 0.001$ , Fig. 3) of S-AKI were significantly higher in level II hospitals than those in tertiary hospitals.

#### **S-AKI patients in Traditional Chinese Medicine hospitals and Western Medicine hospitals (Table 5)**

Table 5  
Comparison between Traditional Chinese Medicine hospitals and Western Medicine hospitals

Variables		TCMHs	WMHs	P value
N (%)		1573(8.0)	18006(92.0)	
Survivors(n)		512(32.9)	8200(46.1)	< 0.001
Age median [IQR]		80(71–85)	78(64–84)	< 0.001
Age stratification(years)	18–39	24(1.5)	924(5.1)	< 0.001
	40–59	133(8.4)	2526(14)	
	60–79	590(37.5)	6703(37.2)	
	≥ 80	826(52.5)	7853(43.6)	
Gender	Female	653(41.5)	6642(36.9)	< 0.001
	Male	920(58.5)	11364(63.1)	
Classification of insurance	BMI	1166(74.2)	9659(53.6)	< 0.001
	RCMTI	109(6.9)	1376(7.6)	
	GMP	133(8.4)	3173(17.6)	
	OPP	113(7.2)	1148(6.4)	
	Others	52(3.3)	2650(14.7)	
Hospital level	Tertiary hospitals	1481(94.2)	16038(89.1)	< 0.001
	Second-class hospital	92(5.8)	1968(10.9)	
Time interval(year)	2005–2011	117(7.4)	1351(7.5)	
	2012–2017	1456(92.6)	16655(92.5)	
Comorbidities(n)	Diabetes	521(33.1)	6503(36.1)	0.02

Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCMHs = traditional Chinese medicine hospitals, WMHs = western medicine hospitals. Values are expressed as the median (interquartile range and N (%)).

Variables		TCMHs	WMHs	P value
	Hypertension	828(52.6)	9399(52.1)	0.73
	CKD stage 2 and 3	299(19)	2645(14.7)	< 0.001
	Malignancy	240(15.2)	3510(19.5)	< 0.001
	Cirrhosis	22(1.4)	778(4.3)	< 0.001
ICU		159(10.1)	6566(36.4)	< 0.001
Types of shock	No shock	1294(82.2)	13323(73.9)	< 0.001
	Septic shock	182(11.6)	3240(18)	< 0.001
	Hypovolemic shock	58(3.7)	930(5.2)	0.01
	Cardiac shock	60(3.8)	879(4.9)	0.06
	Two or more kinds of shock	18(1.1)	327(1.8)	0.05
Types of infection	Pneumonia	1260(80)	13916(77.2)	0.01
	Urinary infection	106(6.7)	1386(7.7)	0.17
	Intra-abdominal infection	86(5.5)	1696(9.4)	< 0.001
	CRBSI	55(3.5)	602(3.3)	0.74
	CNS infection	3(0.2)	44(0.2)	0.68
	Others	256(16.3)	2973(16.5)	0.81
Types of organ function damage	Respiratory insufficiency	850(54)	10947(60.7)	< 0.001
	Acute liver injury	359(22.8)	3641(20.2)	0.01
	DIC	54(3.4)	626(3.5)	0.93
	MODS	305(19.4)	3081(17.1)	0.02

Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCMHs = traditional Chinese medicine hospitals, WMHs = western medicine hospitals. Values are expressed as the median (interquartile range and N (%)).

Variables		TCMHs	WMHs	P value
	Metabolic encephalopathy	34(2.2)	204(1.1)	< 0.001
Expenses	Total expense (Yuan)	46013.3(20515.42-94055.27)	61667.38(29297.85-125052.5)	< 0.001
	Average daily expense (Yuan)	4166.6(2721.57-6398.43)	5413.71(3248.88-8781.84)	< 0.001
	Western medicine expense (Yuan)	9744.02(3425.73-21786.67)	14285.38(5896.72-31166.39)	< 0.001
	Chinese medicine expense (Yuan)	995.2(182.92-3489.11)	73.09(0-686.88)	< 0.001
Length of hospital stay (day)		13(5-22)	13(6-23)	0.03
Abbreviations: BMI = basic medical insurance, RCMTI = rural cooperative medical treatment insurance, GMP = governmental medical payment, OPP = out-of-pocket payments, ER = emergency room, CRBSI = Catheter Related Blood Stream Infection, CNS = central nervous system, DIC = disseminated intravascular coagulation, MODS = multiple organ dysfunction syndrome, TCMHs = traditional Chinese medicine hospitals, WMHs = western medicine hospitals. Values are expressed as the median (interquartile range and N (%)).				

Compared with S-AKI patients seen in the TCMS, the vast majority (92%) of S-AKI patients were treated in WMHs. The survival rate of patients treated in the WMHs was significantly higher than patients treated in TCMHs (45.5% versus 32.5%,  $P < 0.001$ , Fig. 4). Patients from WMHs were younger than those from TCMHs ( $P < 0.001$ ).

The proportion of S-AKI patients admitted in ICU in WMHs was also higher than in TCMHs (36.4% versus 10.1%,  $p < 0.001$ ). The proportion of S-AKI patients with septic shock and abdominal infections in WMHs was higher than in TCMHs hospital ( $p < 0.001$ ). In contrast, there were less patients with lung infections in TCMHs than in WMHs ( $P = 0.01$ ). The proportion of MODS patients admitted in TCMHs was higher than in WMHs (19.4% versus 17.1%,  $p = 0.02$ ).

The total cost, and the average daily cost were all higher in patients of WMHs ( $p < 0.001$ ). S-AKI patients from WMHs had longer length of hospitalization than patients from TCMHs ( $P = 0.03$ ).

## Discussion

In this study, we analyzed the epidemiology of S-AKI in all inpatients, including ICU and non-ICU patients from 158 hospitals in Beijing, China from January 2005 to December 2017. We found the overall incidence of S-AKI was 48.1%, with 59.2% in ICU patients and 31.6% in non-ICU patients, respectively, and overall mortality rate of 55% among the S-AKI patients. Certain risk factors including advanced age, male

and the presence of comorbidities such as hypertension, CKD and liver cirrhosis, and severity of the diseases as assessed by requirements for ICU admission and shock status were significantly associated with the incidence of AKI. Pneumonia was the most likely source of sepsis in this cohort. The reported incidence of S-AKI was higher after KDIGO guideline was used to define AKI. The majority of AKI patients in this study was admitted to tertiary teaching hospitals and western Medicine hospitals.

There is an increasing incidence of AKI worldwide <sup>1-5</sup>. According to the nationwide survey regarding AKI across Mainland China, 28% of AKI episodes occurred in ICU, while 72% occurred in the non-ICU setting. The incidence of S-AKI in LI's paper was only 6.4% <sup>16</sup>. The current literature reported incidence of S-AKI is from 39.4–60.7% in ICU <sup>21,22</sup>, which is consistent with our finding (48%).

Our study showed that certain demographic characteristics, including advanced age, male and the presence of comorbidities such as hypertension, CKD and liver cirrhosis, requirements for ICU admission and shock status were significantly associated with the incidence of AKI. These results were consistent with previous studies <sup>13,23</sup>. However, an Australian S-AKI study revealed female patients had increased risk to develop AKI <sup>2</sup>, whereas some other studies showed no significant difference in age or sex <sup>4,13</sup>. These inconsistent findings may be due to different population and demographic characteristics in each study.

The overall in-hospital mortality among S-AKI in this cohort was 55%, which was higher than the results from previous studies <sup>4,24</sup>. The healthcare system in China is different from some developed countries where patients can have free access to certain procedures such as dialysis therapy <sup>21</sup>, which may be a potential factor contributing to higher mortality rates.

### **Comparison of the incidence of S-AKI between pre and post KDIGO guideline for AKI definition.**

There have been multiple attempts to universally standardize the classification and definition of Acute Kidney Injury (AKI) to enable consistent diagnosis and treatment across different health-care systems. These classifications include the RIFLE (Risk, Injury, Failure, Loss, End Stage), AKIN (Acute Kidney Injury Network) and KDIGO (Kidney Disease: Improving Global Outcomes) which have been good predictors of mortality in critically ill patients <sup>25</sup>. Despite slight variations in the definitions, systematic review has found that these definitions do not significantly differ in their predictive outcomes <sup>26</sup>.

The introduction of new AKI definition in the KDIGO guideline attempted to unify the definition of AKI of both the RIFLE and AKIN criteria. In our study, we found that the change in definitions used may have attributed to an increase in incidence of AKI. According to the AKIN criteria, the incidence of S-AKI in our cohort of patients was 39.7% from the period of 2005–2011. When the updated KDIGO criteria was used, the incidence was higher (48.9%) from the period of 2012–2017. This finding is similar to previous studies <sup>27,28</sup>, which compared utilization of different classifications and found that the AKIN classification had consistently reported lower incidence levels when compared with KDIGO and RIFLE classifications. However, the higher incidence in our study in the later time period may also be attributed

to population aging and the increased incidence of multiple chronic illnesses. Despite the increase in incidence, the mortality rates declined from pre (63.9%) to post (54.4%) KDIGO guideline era.

The declining mortality rates post the KDOGO guideline era may be due to multiple factors including, standardized classifications of AKI leading to early recognition and treatment by clinicians<sup>29-31</sup>; significant advancements in supportive medical technologies such as continuous renal replacement therapy (CRRT) and other measures for treating sepsis, such as early appropriate antibiotic administration and fluid resuscitation and so on<sup>31,32</sup>; majority of patients seeking treatment in tertiary hospital, where the highest level of medical staff and equipment exist<sup>33</sup>.

### **Outcomes between level II and tertiary hospitals**

To the best of our knowledge, present studies in literature are limited and do not directly provide comparisons of the mortality rates between tertiary hospitals and those with limited healthcare resources such as level II, rural or peripheral hospitals. The incidence of S-AKI in level II and tertiary hospitals in this study were similar, 50.8% and 47.7% respectively. The mortality rate in level II hospitals was 9% higher than that in tertiary hospitals.

The higher mortality rates in level II hospitals in our cohort could be attributed to two main reasons. Firstly, the proportion of patients over 80-year-old in level-II hospitals was higher than that in tertiary hospitals (51.7% versus 43.5%). Secondly, there is a limited access to more interventional management strategies in the level-II hospital. For those who had clinical indications for being transferred to a tertiary hospital for advanced treatment but were unable to be transferred in a timely fashion (e.g. due to bed block or change of the treatment goal to conservative treatments), they would only be able to receive limited treatment based on the hospital resource.

### **Traditional Chinese Medicine Hospitals (TCMHs) vs Western Medical Hospitals (WMHs)**

In China, the health care system is uniquely divided into both a western and traditional Chinese medical system<sup>34</sup>. The Chinese cultural heritage has traditionally focused on the administration of traditional Chinese service and products (such as medicinal herbs, acupuncture and dietary therapy), however, there has been a shift by the Chinese government to 'integrate both Chinese and Western medicine' through the implementation of modern medicine and technologies within TCMHs since the 1970's<sup>35</sup>.

A distinct aspect of this study is the comparison of the patient outcomes between TCMHs and WMHs. In our study, the majority of the patients (92%) were diagnosed and treated with S-AKI in WMHs. Furthermore, the number of patients admitted to WMHs was 5.6 times that of the TCMHs in 2018 alone. This can be explained by fewer availability of TCMHs when compared to WMHs. However, in both kinds of hospitals, the incidence of AKI is increasing annually. The mortality rate of S-AKI patients in WMHs is lower than that of patients in TCMHs. This can be explained by more sufficient means of supporting and treating patients in WMHs. This is likely to explain higher costs for patients receiving treatment in WMHs compared to patients in TCMHs.

In addition, many Chinese patients, especially the elderly, take Chinese herbal medicine as the first choice for treating diseases. However, some herbal medicines are also known to cause nephrotoxicity, which is often overlooked by physicians and patients<sup>36</sup>. The incidence of kidney injury induced by Chinese herbal medicines is difficult to assess. One cross-sectional survey of AKI in China<sup>15</sup> found that Chinese patients (71.6%) were more likely to be exposed to traditional Chinese medicine before and during AKI than patients from developed countries (20–50%). This high proportion of nephrotoxic drug exposure is probably consistent with the increasing incidence of drug-induced disease in China<sup>37</sup>. Therefore, the use of Chinese herbal medicine may be a double-edged sword in the treatment of AKI patients.

### **Strengths and Limitations**

To our knowledge, this large retrospective cohort study assessed epidemiological features of S-AKI at the municipal level, in China, consisting 40720 patients and 158 hospitals. This is the first study investigated the impact of levels (level II versus tertiary teaching hospitals) and types of hospitals (TCMHs versus western medicine hospitals) as well as definition of AKI on incidence, and risk factors of S-AKI.

Our study has several limitations. Firstly, our study used a large administrative dataset with insufficient information in the stages of AKI, use of RRT and the long-term prognosis of renal function. Therefore, the epidemiology of S-AKI patients is mainly limited to incidence and hospital mortality. Secondly, even though a number of statistical analyses were conducted in our study, potential confounders still exist, which may have an impact on the study finding. Thirdly, due to the nature of the study using an administrative dataset, a diagnosis of S-AKI in this study was made when based upon a septic patient developed an episode of AKI at the same time. This may overestimate the incidence of S-AKI. Fourthly, the use of different definitions of AKI during our study can lead to variations in overall incidence. From an epidemiologic standpoint it may be difficult to compare results of future studies which highlights the necessity for a standardised and comprehensive AKI classification system. Finally, there were large differences in the patients' numbers in different time periods and different levels and types of hospitals, so the results of the comparisons may have a certain deviation.

## **Conclusions**

AKI is a common complication in all hospitalized patients with sepsis, and its incidence increases over time, especially when ICU admission is required. Our findings provide valuable information about the epidemiology of hospitalized patients with S-AKI in Beijing, China. Exploring interventional strategies to address modifiable risk factors will be important to reduce incidence and mortality of S-AKI.

## **Abbreviations**

AKI	Acute kidney injury
S-AKI	Sepsis-associated acute kidney injury
ICU	Intensive care unit
ESKD	End-stage kidney disease
TCMHs	Traditional Chinese medicine hospitals
WMHs	Western medicine hospitals
CKD	Chronic kidney disease
AKIN	Acute Kidney Injury Network
KDIGO	Kidney Disease Improving Global Outcomes
RIFLE	Risk, Injury, Failure, Loss, End Stage
CRRT	Continuous renal replacement therapy
DM	Diabetes mellitus
HT	Hypertension

## Declarations

### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.


## References

1. Nisula, S. *et al.* Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. *Intensive Care Med* 39, 420–428 (2013).
2. Bagshaw, S. M., George, C., Dinu, I. & Bellomo, R. A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. *Nephrol Dial Transplant* 23, 1203–1210 (2008).
3. Ostermann, M. & Chang, R. W. Acute kidney injury in the intensive care unit according to RIFLE. *Crit Care Med* 35, 1837–1843; quiz 1852 (2007).
4. Hoste, E. A. *et al.* Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive Care Med* 41, 1411–1423 (2015).
5. Xu, X. *et al.* Epidemiology and Clinical Correlates of AKI in Chinese Hospitalized Adults. *Clin J Am Soc Nephrol* 10, 1510–1518 (2015).
6. Uchino, S. *et al.* Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA* 294, 813–818 (2005).

7. Case, J., Khan, S., Khalid, R. & Khan, A. Epidemiology of acute kidney injury in the intensive care unit. *Crit Care Res Pract* 2013, 479730 (2013).
8. Gammelager, H. *et al.* Five-year risk of end-stage renal disease among intensive care patients surviving dialysis-requiring acute kidney injury: a nationwide cohort study. *Crit Care* 17, R145 (2013).
9. Bellomo, R. *et al.* Acute kidney injury in sepsis. *Intensive Care Med* 43, 816–828 (2017).
10. Bagshaw, S. M., George, C., Bellomo, R. & ANZICS Database Management Committee. Early acute kidney injury and sepsis: a multicentre evaluation. *Crit Care*. **12**, R47 2008
11. Jiang, L. *et al.* Epidemiology of acute kidney injury in intensive care units in Beijing: the multi-center BAKIT study. *BMC Nephrol* 20, 468 (2019).
12. Fan, H., Zhao, Y., Chen, G. D., Sun, M. & Zhu, J. H. Health insurance status and risk factors of mortality in patients with septic acute kidney injury in Ningbo, China. *J Int Med Res* 47, 370–376 (2019).
13. *Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury.* *Kidney International Suppl* 2, 1-138 (2012).
14. Bellomo, R. *et al.* Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 8, R204-212 (2004).
15. Mehta, R. L. *et al.* Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 11, R31 (2007).
16. Yang, L. *et al.* Acute kidney injury in China: a cross-sectional survey. *Lancet* 386, 1465–1471 (2015).
17. Ali, T. *et al.* Incidence and outcomes in acute kidney injury: a comprehensive population-based study. *J Am Soc Nephrol* 18, 1292–1298 (2007).
18. Cruz, D. N. & Ronco, C. Acute kidney injury in the intensive care unit: current trends in incidence and outcome. *Crit Care* 11, 149 (2007).
19. Lafrance, J. P., Djurdjev, O. & Levin, A. Incidence and outcomes of acute kidney injury in a referred chronic kidney disease cohort. *Nephrol Dial Transplant* 25, 2203–2209 (2010).
20. James, M. T. *et al.* Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. *Lancet* 376, 2096–2103 (2010).
21. Peters, E. *et al.* A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from The Intensive Care Over Nations audit. *Crit Care* 22, 188 (2018).
22. Zhao, Y. & Yang, L. Perspectives on acute kidney injury strategy in China. *Nephrology (Carlton)* 23 Suppl 4, 100–103 (2018).
23. Khosla, N. *et al.* Preexisting chronic kidney disease: a potential for improved outcomes from acute kidney injury. *Clin J Am Soc Nephrol* 4, 1914–1919 (2009).
24. Fiorentino, M. *et al.* Long-term survival in patients with septic acute kidney injury is strongly influenced by renal recovery. *PLoS One* 13, e0198269 (2018).


25. Levi, T. M. *et al.* Comparison of the RIFLE, AKIN and KDIGO criteria to predict mortality in critically ill patients. *Rev Bras Ter Intensiva* 25, 290–296 (2013).
26. Thomas, M. E. *et al.* The definition of acute kidney injury and its use in practice. *Kidney Int* 87, 62–73 (2015).
27. Sutherland, S. M. *et al.* L. AKI in hospitalized children: comparing the pRIFLE, AKIN, and KDIGO definitions. *Clin J Am Soc Nephrol* 10, 554–561 (2015).
28. Fujii, T., Uchino, S., Takinami, M. & Bellomo, R. Validation of the Kidney Disease Improving Global Outcomes criteria for AKI and comparison of three criteria in hospitalized patients. *Clin J Am Soc Nephrol* 9, 848–854 (2014).
29. Srisawat, N. *et al.* Plasma neutrophil gelatinase-associated lipocalin predicts recovery from acute kidney injury following community-acquired pneumonia. *Kidney Int* 80, 545–552 (2011).
30. Bagshaw, S. M. *et al.* Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. *Intensive Care Med* 35, 871–881 (2009).
31. Meersch, M. *et al.* Long-Term Clinical Outcomes after Early Initiation of RRT in Critically Ill Patients with AKI. *J Am Soc Nephrol* 29, 1011–1019 (2018).
32. Zarbock, A. *et al.* Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. *JAMA* 315, 2190–2199 (2016).
33. Wang, S. T. *et al.* F. A study of the referral patterns of obstetric clinics and the performance of receiving neonatal intensive care units in Taiwan. *Public Health* 111, 149–152 (1997).
34. Zhu, D., Shi, X., Nicholas, S. & He, P. Regional disparities in health care resources in traditional Chinese medicine county hospitals in China. *PLoS One* 15, e0227956 (2020).
35. Wang, L. *et al.* An investigation into Traditional Chinese Medicine Hospitals in China: Development Trend and Medical Service Innovation. *Int J Health Policy Manag* 6, 19–25 (2017).
36. Yang, B. *et al.* Nephrotoxicity and Chinese Herbal Medicine. *Clin J Am Soc Nephrol* 13, 1605–1611 (2018).
37. Katsoulis, E. *et al.* Lipotoxicity in renal proximal tubular cells: Relationship between endoplasmic reticulum stress and oxidative stress pathways. *Free Radic Biol Med* 48, 1654–1662 (2010).

## Figures




**Figure 1**

The hospital survival probability curves of all patients with sepsis. Survival curves of patients classified according to the presence (highlighted in blue) or absence (highlighted in red) of AKI during hospital stay. Patients with AKI had significantly lower hospital survival rate than patients without (45.0% versus 70.7% respectively;  $p < 0.001$ ).




**Figure 2**

The hospital survival probability curves of patients with S-AKI classified according to admission date: before (2005-2011, highlighted in blue) or after (2012-2017, highlighted in red) the KDIGO guideline era. Patients admitted after the KDIGO guideline era had higher hospital survival rate than patients admitted before (45.6% versus 36.1% respectively;  $p < 0.001$ ).



**Figure 3**

The hospital survival probability curves of patients with S-AKI classified according to hospital levels: level II hospitals (highlighted in blue) and tertiary hospitals (highlighted in red) . The survival rate of S-AKI were significantly lower in level II hospitals than those in tertiary hospitals (37.9% versus 45.9% respectively;  $p < 0.001$ ).



**Figure 4**

The hospital survival probability curves of patients with S-AKI classified according to hospital types: Traditional Chinese Medicine hospitals (TCMHs, highlighted in red) and Western Medicine hospitals (WMHs, highlighted in blue). The survival rate of patients treated in the WMHs was significantly higher than patients treated in TCMHs (45.5% versus 32.5% respectively;  $p < 0.001$ ).